NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries
TORONTO and TEL AVIV, Israel, May 16, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the “Company” or “NurExone“) (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that the Company has received an issue notification from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent NO. 11,648,260, granted for the period of 20 years from filing date until March 27, 2039. The patent protects NurExone’s Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment.
The Patent is a result of a productive collaboration between the Technion (the Israel Institute of Technology) and Tel Aviv University. Both Technology transfer companies, Technion Research and Development Foundation Ltd. and Ramot at Tel Aviv University Ltd are the assignees on the granted patent. NurExone has an exclusive license on the granted patent. One of the inventors, Dr. Nisim Perets is currently leading the technology transfer activities in NurExone’s research and development team.
In order to strengthen the Exo-PTEN technology platform protection as well as to further expand NurExone’s intellectual property portfolio, the Company proceeds in a filing of a child ‘continuation’ patent application with the USPTO, to include additional claims on the method of treatment and indication of the Exo-PTEN platform. In parallel, counterparts of the U.S. patent are being examined in different countries around the world.
According to Patent Attorney Bat Ami Gotliv, PhD, who consults the Company – the grant of this patent is a significant millstone for NurExone and, based on the Company’s promising Intellectual Property portfolio, an initial step for expanding its proprietary estate and becoming a leading company in the field of Central Nervous System and neurological diseases treatment.
“We are pleased to have been granted a patent for our propriety drug product, Exo-PTEN,” said Dr. Lior Shaltiel, CEO of NurExone. “The latest patent expands our intellectual property portfolio and enables us to be the exclusive provider of this unique exosome-based therapy that is designed to treat acute spinal cord injuries.”
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.
ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the Company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For further information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Inbar Paz-Benayoun, Adv. Head of Communications and Investor Relations
Phone: +972-52-3966695
Email: info@nurexone.com
Investor Relations (Canada)
Phone: +1 905-347-5569
Email: IR@nurexone.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
